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No	   evidence	   to	   suggest	   that	   the	   use	   of	   acetylcholinesterase	  
inhibitors	  confounds	   the	  results	  of	   two	  blood-­‐based	  biomarker	  
studies	  in	  Alzheimer’s	  disease	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Abstract	  
Background:	   There	   is	   an	   urgent	   need	   to	   discover	   Alzheimer’s	   disease	   (AD)	  biomarkers	   that	   are	   both	   easily	   measured	   and	   reliable.	   Research	   into	   blood-­‐based	   biomarkers	   for	   AD	   using	   transcriptomics	   and	   proteomics	   has	   been	   an	  attractive	  and	  promising	  area	  of	  research.	  However,	  to	  date	  researchers	  have	  not	  looked	  into	  the	  possibility	  of	  AD	  medication	  being	  a	  confounding	  factor	  in	  these	  studies.	  
	  
Objective:	   This	   study	   explored	   whether	   acetylcholinesterase	   inhibitors	  (AchEIs),	  the	  main	  class	  of	  AD	  medication,	  are	  a	  confounding	  factor	  in	  AD	  blood	  biomarker	  studies.	  
	  
Methods:	  The	  most	  promising	  blood	  transcriptomic	  and	  proteomic	  biomarkers	  from	  two	  recent	  studies	  were	  analyzed	   to	  determine	   if	   they	  were	  differentially	  expressed	  between	  AD	  subjects	  on	  AchEIs	  and	  subjects	  that	  were	  not.	  	  
Results:	   None	   of	   the	   gene	   or	   protein	   biomarkers	   analyzed	   were	   found	   to	   be	  significantly	  altered	  between	  subjects	  in	  either	  group.	  	  
Conclusion:	  This	  study	  found	  no	  evidence	  that	  AchEIs	  are	  a	  confounding	  factor	  in	   these	   published	   AD	   blood	   biomarker	   studies.	   Further	   work	   is	   needed	   to	  confirm	  that	  this	  is	  also	  the	  case	  for	  other	  proposed	  biomarkers.	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1.	  Introduction	  	  Alzheimer’s	   disease	   (AD)	   is	   a	   common,	   costly	   and	   fatal	   neurodegenerative	  disorder.	   It	   manifests	   in	   the	   form	   of	   progressive	   cognitive	   decline,	   including	  memory	   loss,	   executive	   dysfunction,	   psychiatric	   symptoms	   and	   behavioral	  disturbances	   [1].	   Currently,	   a	   definitive	   diagnosis	   of	   AD	   can	   only	   be	   obtained	  after	   post-­‐mortem	   dissection	   of	   brain	   tissue.	   AD	   diagnosis	   therefore	   relies	   on	  robust	   clinical	   evaluation,	   sometimes	   including	   assessment	   of	   pathology	   using	  cerebrospinal	   fluid	   (CSF)	   biomarkers	   [2],	   or	   pathology	   measures	   from	   brain	  scans;	   usually	   Magnetic	   Resonance	   Imaging	   (MRI)	   or	   Positron	   Emission	  Tomography	  (PET)	  	  [3,4].	  	  Despite	  these	  efforts,	  diagnosis	  of	  AD	  remains	  difficult,	  especially	  in	  areas	  where	  access	   to	   advanced	   neuroimaging	   equipment	   remains	   limited.	   A	   lumbar	  puncture	  to	  acquire	  CSF	  for	  analysis	  is	  also	  relatively	  invasive	  and	  inappropriate	  in	  certain	  clinical	  environments.	   It	  has	  been	  suggested	   that	  up	   to	   two-­‐thirds	  of	  dementia	  patients	  go	  un-­‐diagnosed	  [5],	  and	  that	  by	  the	  time	  an	  AD	  diagnosis	   is	  made,	  the	  underlying	  pathological	  processes	  have	  been	  developing	  for	  around	  20	  years	  [6].	  There	  is	  therefore	  an	  urgent	  need	  to	  develop	  investigative	  techniques	  that	  are	  cost	  effective,	  easy	  to	  administer,	  and	  capable	  of	  aiding	  the	  diagnosis	  of	  AD	  in	  its	  early	  stages.	  Though	  undoubtedly	  challenging,	  this	  may	  prove	  useful	  for	  enriching	  clinical	  trials	  for	  subjects	  whose	  pathology	  is	  less	  advanced.	  	  Recently,	  the	  analysis	  of	  blood	  samples	  to	  develop	  a	  blood-­‐based	  diagnostic	  test	  has	   been	   an	   attractive	   area	   in	   AD	   biomarker	   research.	   Blood	   samples	   of	   AD	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subjects	   can	   be	   collected	   with	   relative	   ease,	   and	   analyzed	   to	   determine	  differences	  in	  protein	  or	  messenger	  RNA	  (mRNA)	  quantity	  that	  might	  elucidate	  underlying	  biological	  changes	  in	  the	  disease	  state	  	  [5].	  Studies	  such	  as	  Booij	  et	  al.	  [7],	  Fehlbaum-­‐Beurdeley	  et	  al.	  [8]	  and	  more	  recently	  Lunnon	  et	  al.	  2012	  [9]	  have	  demonstrated	  that	  whole-­‐blood	  profiling	  of	  mRNA	  can	  generate	  evidence	  of	  AD	  associated	   differences	   in	   gene	   expression.	   Similarly,	   studies	   such	   as	   Ray	   et	   al.	  	  [10],	  Doecke	  et	  al.	   	   [11],	  and	  Sattlecker	  et	  al.	   	   [12]	  have	  analyzed	  blood	  protein	  quantities	   to	   identify	   proteins	   with	   significantly	   altered	   blood	   levels	   in	   AD.	  Zurbig	  and	  Jahn	  [13],	  Lista	  et	  al.	  [14],	  Kiddle	  et	  al.	  	  [15]	  and	  Chiam	  et	  al.	  [16]	  have	  also	  recently	  reviewed	  the	  blood-­‐based	  proteins	  most	  commonly	  associated	  with	  AD,	  finding	  a	  modest	  degree	  of	  replication	  between	  studies.	  Given	  the	  prospect	  of	  a	   cheap	   and	   convenient	   diagnostic	   test	   should	   success	   be	   achieved,	   it	   is	   likely	  that	   research	   into	   blood-­‐based	   biomarkers,	   while	   not	  without	   limitations,	   will	  continue	  to	  be	  an	  appealing	  avenue	  in	  AD	  biomarker	  discovery	  	  [17,18].	  	  	  Although	  there	  has	  been	  a	  significant	  amount	  of	  research	  generated	  in	  the	  field,	  very	   little	   has	   been	   done	   to	   look	   into	   the	   potential	   effects	   of	   medication	   as	   a	  confounding	  factor	  in	  blood-­‐based	  biomarker	  discovery.	  This	  is	  important	  as	  the	  medication	   an	   individual	   is	   receiving	   depends	   largely	   on	   their	   diagnosis.	  Medication	  could	  potentially	  affect	  the	  composition	  of	  biological	  molecules	  in	  the	  blood.	  For	  example,	  AD	  patients	  are	  often	  placed	  on	  a	  wide	  range	  of	  psychotropic	  drugs	  and	  recent	  evidence	  suggests	  that	  psychotropic	  drugs	  affect	  the	  expression	  of	  AD	  related	  genes	  in	  blood	  	  [19].	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There	  are	  currently	  two	  classes	  of	  drugs	  used	  to	  treat	  the	  cognitive	  symptoms	  of	  AD,	  acetylcholinesterase	  inhibitors	  (AchEIs)	  and	  memantine	  (an	  NMDA	  receptor	  antagonist).	   Of	   these,	   AchEIs	   are	   the	   most	   common	   class	   of	   drug	   used	   in	   the	  treatment	   of	   AD	   [20].	   These	   drugs	   act	   by	   inhibiting	   the	   enzyme	  acetylcholinesterase.	   This	   prevents	   the	   breakdown	   of	   the	   neurotransmitter	  acetylcholine	  at	  synapses,	  thus	  increasing	  the	  strength	  of	  neural	  transmission	  in	  the	   brain	   [21,22].	   Treatment	   with	   AchEIs	   has	   been	   found	   to	   modulate	   the	  expression	  of	  pro-­‐	  and	  anti-­‐inflammatory	  cytokines	   in	  the	  blood	  of	  AD	  patients	  	  [23].	   	  Given	  the	  high	  prevalence	  of	  AchEI	  use	  among	  AD	  subjects,	  it	  is	  therefore	  pertinent	   to	   determine	   if	   the	   potential	   gene	   and	   protein	   blood	   biomarkers	  identified	   in	  studies	  are	   indeed	  due	   to	  biological	  changes	  as	  a	  result	  of	  AD	  and	  not	  due	  to	  the	  effects	  of	  these	  drugs.	  	  	  This	   study	   seeks	   to	   build	   on	   the	   results	   from	   Lunnon	   et	   al.	   2012	   [9]	   and	  Sattlecker	   et	   al.	   [12]	   by	   analyzing	   the	   most	   promising	   gene	   and	   protein	  biomarkers	  identified	  in	  AD	  subjects	  by	  both	  studies	  and	  determining	  if	  the	  use	  of	  AchEIs	  confounds	  the	  association	  between	  these	  blood-­‐based	  biomarkers	  and	  AD.	  	  	  
2.	  Methods	  and	  Materials	  
2.1	  Samples	  and	  clinical	  data	  from	  the	  AddNeuroMed	  cohort	  As	  described	  in	  Lunnon	  et	  al.	  2012	  [9]	  and	  Sattlecker	  et	  al.	   [12],	  blood	  samples	  were	   obtained	   from	   subjects	   participating	   in	   the	   AddNeuroMed	   (ANM)	   study	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[24-­‐26].	  Subjects	  were	  located	  at	  six	  different	  study	  sites	  across	  Europe,	  namely	  London,	   Lodz,	   Toulouse,	   Perugia,	   Kuopio	   and	   Thessaloniki.	   Informed	   consent	  was	   appropriately	   taken	   according	   to	   the	   Declaration	   of	   Helinski	   (1991)	   and	  ethical	  approval	  was	  obtained	  at	  each	  site.	  A	  diagnosis	  of	  AD	  was	  attained	  using	  the	  NINCDS-­‐ADRDA	   criteria	   	   [27]	   and	   the	  Diagnostic	   and	   Statistical	  Manual	   of	  Mental	  Disorders	  (DSM-­‐IV).	  	  All	   subjects	   went	   through	   a	   semi-­‐structured	   interview	   in	   order	   to	   collect	   the	  necessary	   demographic	   and	   medical	   information.	   This	   included	   an	   array	   of	  neuropsychological	   assessments	   such	   as	   the	   Mini	   Mental	   State	   Examination	  	  [28],	   Global	   Deterioration	   Scale	   [29]	   and	   the	   Alzheimer’s	   Disease	   Assessment	  Scale-­‐Cognitive	   subscale	   [30].	   Information	   regarding	   the	   kind	   of	  neuropsychiatric	   medication	   each	   subject	   was	   currently	   prescribed	   was	   also	  obtained.	  	  	  Blood	   samples	   were	   drawn	   from	   subjects	   by	   venipuncture	   and	   collected	   in	  PAXgen	   vacutainer	   tubes	   (Qiagen)	   for	   RNA	   analysis	   and	   EDTA	   glass	   tubes	   for	  proteomic	  analysis.	  	  Relevant	  demographics	  and	  clinical	  data	  for	  these	  subjects	  were	  extracted	  from	  the	  AddNeuroMed	  database	  using	  CohortExplorer	  	  [31].	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2.2	  Gene	  Expression	  Study	  Blood	   samples	   collected	   from	   the	   ANM	   cohort	   were	   analyzed	   to	   determine	  mRNA	   gene	   expression	   profiles.	   Full	   details	   of	   the	   data	   collection	   and	  preprocessing	  procedure	  can	  be	  found	  in	  Lunnon	  et	  al.	  2012	  [9]	  and	  Voyle	  et	  al.	  (manuscript	  in	  preparation),	  and	  is	  only	  discussed	  briefly	  here.	  	  	  
2.2.1	  Data	  Collection	  The	  vacutainer	  tubes	  containing	  blood	  samples	   for	  RNA	  analysis	  were	   inverted	  8-­‐10	  times	  and	  stored	  at	  -­‐24°C	  for	  24h	  before	  lowering	  the	  temperature	  to	  -­‐80°C	  until	   RNA	   extraction.	   RNA	   was	   extracted	   using	   the	   PAXgene	   blood	   RNA	   kit	  (Qiagen),	   following	  the	  manufacturer’s	  protocol.	  The	  2100	  Bioanalyser	  (Agilent	  Technologies)	  was	  then	  used	  to	  evaluate	  the	  quality	  of	  the	  extracted	  RNA.	  Only	  RNA	  samples	   that	  exceeded	  a	  RNA	   integrity	  number	   (RIN)	  of	  7.0	  were	  used	   in	  the	  analysis.	  	  Microarray	   processing	   was	   conducted	   at	   the	   University	   of	   California	   in	   Los	  Angeles.	   The	   RNA	   samples	   were	   processed	   on	   Illumina	   Human	   HT-­‐12	   v3	  Expression	   BeadChips	   (Illumina),	   each	   containing	   48,803	   probes.	   RNA	   was	  amplified	  using	  the	  Illumina	  TotalPrep	  RNA	  Amplification	  Kit	  (Ambion)	  and	  gene	  expression	   values	   were	   obtained	   using	   the	   Lumi	   package	   within	   the	   R	  Bioconductor	  project	  	  [32].	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2.2.2	  Preprocessing	  
Raw	  gene	  expression	  data	  was	  subject	  to	  a	  model	  based	  background	  correction	  for	   bead	   array	   [33].	   Negative	   bead	   expression	   levels	   were	   used	   to	   correct	   for	  background	  noise.	  The	  data	  was	  then	  log	  base	  2	  transformed	  and	  robust	  spline	  normalized	  before	  outlying	   samples	  were	   iteratively	   identified	  by	   fundamental	  network	   concepts	   and	   removed	   [32,34].	   To	   remove	   any	   batch	   effects	   we	  adjusted	  for	  technical	  categorical	  variables	  using	  ComBat	  [35].	  The	  first	  principal	  component	   across	   housekeeping	   probes	   was	   taken	   and	   regressed	   against	  technical	   variables	   and	   phenotype	   in	   order	   to	   account	   for	   the	   principal	  component	  across	  housekeeping	  probes.	  Variables	  significantly	  associated	  with	  the	  first	  principal	  component	  where	  then	  regressed	  against	  expression	  for	  each	  probe,	   and	   the	  mean	  adjusted	   residuals	   taken	   forward	   for	   all	   further	   analyses.	  Finally,	  the	  data	  was	  subset	  to	  probes	  that	  could	  be	  reliably	  detected	  in	  at	  least	  80%	  of	   samples	   in	   each	   diagnostic	   group.	   Subjects	  were	   excluded	   if	   lab-­‐based	  investigations	   highlighted	   discrepancies	   between	   recorded	   sex	   and	   sex	  determined	  by	  the	  XIST	  gene.	  
2.2.3	  Probe	  Selection	  	  Probes	   that	   had	   a	   significant	   difference	   in	   signal	   between	   AD	   subjects	   and	  controls	   were	   identified	   from	   Lunnon	   et	   al.	   2012	   	   [9].	   The	   most	   significant	  probes	   were	   identified	   through	   a	   dual-­‐criteria.	   Firstly	   a	   Bonferroni	   correction	  was	  applied	  to	  the	  p-­‐values	  reported	  by	  Lunnon	  et	  al.	  2012	  	  [9]	  (α=0.05/19,161).	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Any	  probe	  that	  met	  the	  corrected	  threshold	  of	  p-­‐value	  <	  α	  and	  had	  an	  absolute	  fold	  change	  of	  	  >0.5	  was	  identified	  for	  further	  analysis.	  	  
	  
2.2.4	  Subject	  Selection	  In	  Lunnon	  et	  al.	  2012	  [9],	  a	  total	  of	  356	  samples	  (116	  control,	  127	  mild	  cognitive	  impairment	   (MCI),	   113	   AD)	   were	   put	   through	   RNA	  microarray	   processing.	   Of	  this	  a	  subset	  was	  extracted	  for	  analysis	  in	  our	  study,	  as	  described	  below.	  Of	  the	  113	   AD	   subjects,	   100	   had	   complete	   demographic	   data	   for	   medication,	   age,	  gender,	   MMSE	   score,	   and	   APOE	   status.	   It	   was	   decided	   that	   subjects	   on	  memantine,	  another	  form	  of	  AD	  cognitive	  drug	  would	  be	  excluded	  as	  there	  were	  too	   few	   subjects	   to	   conduct	   a	   conclusive	   analysis.	   Therefore	   5	   subjects	   on	  memantine	   and	   6	   subjects	   on	   both	  AchEI	   and	  memantine	  were	   excluded.	   This	  resulted	  in	  a	  total	  of	  89	  AD	  subjects	  for	  gene	  expression	  analysis.	  	  	  
2.3	  Proteomic	  Study	  Similar	  to	  the	  gene	  expression	  analysis	  described	  above,	  blood	  samples	  collected	  from	  the	  ANM	  cohort	  were	  analyzed	  to	  determine	  protein	  quantities.	  A	  detailed	  account	   of	   the	   data	   collection	   and	   preprocessing	   procedure	   can	   be	   found	   in	  Sattlecker	  et	  al.	  [12]	  and	  is	  described	  only	  briefly	  here.	  	  	  
2.3.1	  Data	  Collection	  EDTA	  tubes	  with	  the	  blood	  samples	  were	  centrifuged	  at	  2,000	  rpm	  at	  4°C	  for	  10	  minutes	   within	   approximately	   2	   hours	   of	   collection.	   The	   resulting	   plasma	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supernatant	  was	  then	  collected	  and	  divided	  into	  aliquots	  before	  being	  frozen	  at	  -­‐80°C	  until	  protein	  measurement.	  	  	  	  Protein	  quantities	  were	  measured	  using	  the	  new	  Slow	  Off-­‐rate	  Modified	  Aptamer	  (SOMAmer)-­‐based	   capture	   array	   known	   as	   “SOMAscan”	   (SomaLogic,	   Inc).	  Chemically	  modified	   nucleotides	   are	   used	   to	   transform	   a	   protein	   signal	   into	   a	  nucleotide	  signal	  	  [36].	  Microarrays	  were	  then	  used	  to	  quantify	  the	  signal	  using	  relative	   fluorescence.	   A	   total	   of	   1,001	   human	   proteins,	   representing	   different	  molecular	  pathways	  and	  gene	  families,	  were	  quantified	  this	  way.	  	  
	  
2.3.2	  Preprocessing	  Hybridization	   controls	   on	   the	   microarray	   were	   used	   to	   monitor	   sample-­‐by-­‐sample	  variability	  in	  hybridization,	  while	  the	  median	  signal	  across	  all	  SOMAmers	  was	   used	   to	   monitor	   overall	   technical	   variability.	   Using	   both	   the	   resulting	  hybridization	  and	  median	  scale	  factors,	  data	  across	  samples	  was	  normalized.	  An	  acceptance	   criterion	   of	   0.4-­‐2.5	   was	   used	   for	   values	   based	   on	   historic	   trends.	  SOMAmer-­‐by-­‐SOMAmer	   calibration	   was	   established	   through	   the	   repeated	  measurement	  of	  calibration	  samples.	  A	  calibration	  scale	  factor	  is	  then	  generated	  using	  historic	   values	  of	   these	   calibration	   samples.	  The	   acceptance	   criterion	   for	  calibrator	  scale	   factors	   is	   that	  95%	  of	  SOMAmers	  must	  have	  a	  calibration	  scale	  factor	  within	  60.4	  of	  the	  median	  	  [12].	  	  All	  measurements	  obtained	  were	  log	  2	  transformed.	  Seven	  sample	  outliers	  were	  identified	  using	  principal	  component	  analysis	  in	  R	  and	  were	  thus	  removed	  from	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downstream	  processing	  	  [12].	  	  	  
2.3.3	  Probe	  Selection	  Sattlecker	   et	   al.	   [12]	   had	   previously	   identified	   four	   proteins	   (prostate-­‐specific	  antigen	   complexed	   to	   α1-­‐antichymotrypsin,	   clusterin,	   pancreatic	   prohormone	  and	  fetuin	  B)	  that	  were	  found	  to	  have	  significantly	  altered	  levels	  (q-­‐value	  <	  0.05)	  in	  AD	  subjects	  when	  compared	  to	  healthy	  elderly	  controls.	  These	   four	  proteins	  were	  selected	  for	  the	  analysis.	  	  
2.3.4	  Subject	  Selection	  In	  Sattlecker	  et	  al.	  [12],	  a	  total	  of	  415	  ANM	  samples	  (110	  control,	  109	  MCI,	  196	  AD)	   underwent	   SOMAscan	   proteomic	   analysis.	   Like	   in	   the	   gene	   expression	  portion	  of	   the	   study,	   a	   subset	   of	   this	  was	   extracted	   for	  data	   analysis	   using	   the	  same	  criteria.	  Of	   the	  196	  AD	  subjects,	  189	  had	  complete	  demographic	  data	   for	  medication,	   age,	   gender,	   MMSE	   score,	   and	   APOE	   status.	   After	   8	   subjects	   on	  memantine	  and	  13	  subjects	  on	  both	  AchEI	  and	  memantine	  were	  excluded,	  a	  total	  of	  168	  AD	  subjects	  were	  selected	  for	  the	  proteomic	  portion	  of	  the	  study.	  	  
2.4	  Statistical	  power	  calculations	  	  Power	  calculations	  were	  performed	  using	  the	  ‘pwr.f2.test’	  in	  the	  ‘pwr’	  R	  package,	  based	   on	   the	   approach	   of	   Cohen	   1988	   [37].	   Based	   on	   the	   recommendation	   by	  Cohen	  (1988)	  f2	  =	  0.02,	  	  0.15	  and	  0.35	  were	  used	  to	  indicate	  a	  small,	  medium	  and	  large	   effect	   size	   respectively.	   A	   statistical	   significance	   level	   of	   0.005	   was	  required,	   to	   represent	   a	  Bonferroni	  multiple	   testing	   correction	   for	   10	  markers	  (midway	  between	  number	  of	  gene	  expression	  and	  protein	  markers	  studied).	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2.5	  Data	  Analysis	  	  All	  data	  analysis	  was	  performed	  using	  R.	  The	  AD	  subjects	  that	  were	  selected	  for	  either	  the	  gene	  expression	  study	  or	  the	  proteomic	  study	  were	  further	  split	   into	  two	  groups	  based	  on	  the	  type	  of	  cognitive	  enhancing	  AD	  medication	  they	  were	  on.	   The	   first	   group	   comprised	   those	   on	   AchEIs,	   while	   the	   second	   group	  comprised	  those	  subjects	  not	  on	  any	  form	  of	  cognitive	  enhancing	  AD	  medication	  (non-­‐AchEI).	  The	  gene	  expression	  study	  had	  72	  subjects	  in	  the	  AchEI	  group	  and	  17	   subjects	   in	   the	   non-­‐AchEI	   group.	   Similarly,	   the	   proteomic	   study	   had	   129	  subjects	   in	   the	  AchEI	   group	   and	   39	   subjects	   in	   the	   non-­‐AchEI	   group.	   For	   both	  studies,	  an	  analysis	  was	  then	  conducted	  between	  the	  AchEI	  group	  and	  non-­‐AchEI	  group	   to	   see	   if	   there	   was	   any	   significant	   difference	   in	   gene	   expression	   and	  protein	  quantity.	  	  	  Firstly	  the	  demographic	  data	  was	  analyzed	  to	  ensure	  that	  confounding	  variables	  could	  be	   identified.	  Discrete	  variables	  such	  as	  gender	  and	  APOE	  ε4	  allele	  status	  were	   analyzed	   using	   Fisher’s	   exact	   test.	   Continuous	   variables	   such	   as	   age	   and	  MMSE	  score	  were	  analyzed	  using	  linear	  modeling.	  A	  threshold	  of	  p-­‐value	  <	  0.05	  was	  set	  to	  identify	  if	  any	  of	  the	  variables	  differed	  between	  both	  AchEI	  and	  non-­‐AchEI	  groups.	  	  	  An	   analysis	   was	   then	   conducted	   on	   the	   genes	   and	   proteins	   that	   were	   pre-­‐selected	  to	  determine	  if	  there	  was	  a	  significant	  difference	  in	  gene	  expression	  or	  protein	  levels	  between	  AD	  patients	  on	  AchEIs	  and	  those	  that	  were	  not.	  This	  was	  conducted	   using	   linear	   modeling	   with	   study	   site	   added	   as	   a	   covariate	   in	   the	  analysis.	   The	   p-­‐values	   obtained	   were	   then	   adjusted	   for	   multiple	   testing	   by	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applying	  the	  false	  discovery	  rate	  (FDR).	  A	  threshold	  of	  q-­‐value	  <	  0.05	  was	  used	  to	  identify	  differentially	  expressed	  genes	  and	  differences	  in	  blood	  protein	  quantity.	  Box	   plots	   were	   created	   for	   genes	   or	   proteins	   of	   interest	   and	   for	   these,	   111	  controls	  (non-­‐AD	  subjects)	  from	  the	  ANM	  cohort	  were	  included	  to	  provide	  visual	  comparison	  of	  any	  variation	  between	  the	  groups.	  	  	  
3.	  Results	  
3.1	  Statistical	  power	  To	  examine	  our	  ability	  to	  detect	  small,	  medium	  and	  large	  effects	  of	  AchEIs	  on	  blood	  marker	  levels,	  we	  performed	  statistical	  power	  calculations	  using	  a	  significance	  level	  of	  p	  =	  0.005.	  Figure	  1	  shows	  that	  the	  gene	  expression	  study	  (n	  =	  89)	  has	  ~2.3%,	  ~47%	  or	  ~96%	  statistical	  power	  to	  detect	  a	  small,	  medium	  or	  large	  effect	  of	  AchEIs	  on	  blood	  gene	  expression	  markers.	  It	  also	  shows	  that	  the	  proteomics	  study	  (n	  =	  168)	  has	  ~5%,	  ~89%	  or	  ~100%	  statistical	  power	  to	  detect	  a	  small,	  medium	  or	  large	  effect	  of	  AchEIs	  on	  blood	  protein	  markers.	  It	  also	  shows	  that	  even	  a	  study	  with	  a	  sample	  size	  of	  500	  would	  only	  have	  ~30%	  power	  to	  detect	  a	  small	  effect	  of	  medication	  on	  a	  blood	  marker.	  
3.2	  Gene	  Expression	  Study	  To	  investigate	  the	  effect	  of	  AchEIs	  on	  blood	  gene	  expression	  markers	  of	  AD,	  we	  examined	   gene	   expression	   levels	   in	   89	   AD	   subjects	   with	   gene	   expression,	  demographic	   and	   medication	   data.	   No	   significant	   differences	   in	   gender,	   age,	  
APOE	  status	  or	  MMSE	  scores	  were	  seen	  between	  the	  AchEI	  group	  and	  the	  non-­‐AchEI	  group	  (p	  <	  0.05;	  Table	  1).	  As	  a	  result,	  none	  of	  the	  demographic	  variables	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were	   factored	   in	   as	   covariates	   in	   the	   analysis	   of	   probe	   signal	   between	   both	  groups.	  	  	  When	   a	   Bonferroni	   correction	   was	   applied,	   23	   probes	   were	   identified	   that	  passed	  the	  dual-­‐criteria	  that	  had	  been	  set	  (p-­‐value	  <	  α	  and	  absolute	  fold	  change	  >	  0.5).	  These	  23	  probes	  were	  thus	  selected	  for	  analysis	  (Table	  2).	  	  After	  multiple	   testing	   correction	  was	   applied,	   none	   of	   the	   23	   probes	   analyzed	  showed	   any	   significant	   difference	   in	   signal	   strength	   between	   the	   group	   on	  AchEIs	   and	   the	   group	   without	   (q-­‐value	   <	   0.05).	   Six	   probes	   (UQCRH,	   ATP5O,	  ATP5EP2,	   C14orf156,	   ZMAT2	   and	   LOC653658)	   were	   found	   to	   be	   nominally	  significantly	  (p	  <	  0.05)	  associated	  with	  the	  use	  of	  AchEIs	  (Table	  2).	  The	  box	  plots	  for	  these	  six	  probes	  are	  shown	  in	  Figure	  2.	  Only	  two	  of	  these	  –	  LOC653658	  and	  C14orf156	  –	  were	  still	  nominally	  associated	  with	  medication	  use	  when	  presence	  or	   absence	   of	   APOE	   ε4	   (and	   it’s	   interaction	   with	   medication	   use)	   was	   also	  accounted	   for	   in	   the	  model.	   Visually	   there	   does	   not	   appear	   to	   be	   a	   significant	  difference	  in	  expression	  of	  these	  genes	  between	  groups.	  	  
3.3	  Proteomic	  Study	  For	  the	  168	  AD	  subjects	  with	  proteomic,	  demographic	  and	  medication	  data,	  no	  significant	   differences	   in	   gender,	   age,	   APOE	   status	   or	   MMSE	   scores	   were	  observed	  between	  the	  AchEI	  group	  and	  the	  non-­‐AchEI	  group	  (p	  <	  0.05;	  Table	  3).	  None	   of	   these	   variables	  were	   thus	   factored	   in	   as	   covariates	   for	   the	   proteomic	  analysis.	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  The	  four	  proteins	  analyzed	  showed	  no	  significant	  difference	  in	  quantity	  between	  both	  groups	  in	  a	  linear	  model,	  with	  none	  passing	  significance	  thresholds	  either	  at	  the	   nominal	   (p	   <	   0.05)	   or	  multiple	   testing	   corrected	   (q	   <	   0.05)	   threshold	   (See	  Table	  4).	  	  
4.	  Discussion	  	  The	   analysis	   conducted	   shows	   that	   none	   of	   the	   biomarkers	   studied	   are	  differentially	   expressed	   in	   subjects	   taking	   AchEIs.	   Our	   sample	   had	   reasonable	  statistical	   power	   to	   detect	   large	   effects	   on	   gene	   expression	  markers,	   and	   both	  medium	  or	   large	  effects	  on	  protein	  markers.	  This	   implies	   that	  AchEIs	  are	  not	  a	  large	   confounding	   factor	   affecting	   the	   most	   promising	   gene	   or	   protein	  biomarkers	  identified	  in	  the	  studies	  by	  Lunnon	  et	  al.	  2012	  	  [9]	  and	  Sattlecker	  et	  
al.	  [12].	  If	  AchEIs	  had	  been	  found	  to	  be	  a	  large	  confounding	  factor,	  it	  would	  have	  undermined	  the	  diagnostic/enrichment	  potential	  of	  the	  biomarkers	  identified	  in	  those	  studies.	  The	  results	  of	  this	  study,	  though	  small	   in	  scope	  and	  by	  no	  means	  comprehensive,	   are	   therefore	   encouraging	   and	   strengthen	   the	   validity	   of	   these	  studies.	   As	   the	   first	   study	   to	   examine	   the	   possibility	   of	   AD	   blood	   biomarkers	  being	  confounded	  by	  AchEIs,	   it	   also	  highlights	  a	  previously	  neglected	  potential	  confounding	  variable.	  	  	  In	  this	  study	  the	  sample	  size	  of	  both	  groups	  tested	  was	  notably	  imbalanced.	  The	  number	   of	   subjects	   in	   the	   group	   not	   on	   any	   AD	   medication	   was	   significantly	  smaller	   than	   the	   group	   on	   AchEIs	   in	   both	   the	   gene	   expression	   and	   proteomic	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analysis.	   This	   is	   understandable	   since	  most	   AD	   patients	  would	   be	   expected	   to	  have	   some	   sort	   of	   cognitive	   enhancing	  medication	   as	   treatment.	   It	  would	   also	  have	   been	   interesting	   to	   include	   an	   analysis	   of	   subjects	   using	  memantine,	   the	  other	  main	  class	  of	  AD	  cognitive	  drugs.	  Yet	  in	  this	  study	  too	  few	  subjects	  were	  on	  memantine	   to	   allow	   a	   thorough	   investigation	   of	   this.	   This	   limitation	   could	   be	  overcome	  should	  larger	  studies	  be	  conducted	  in	  the	  future.	  	  	  While	   in	   this	   study	   AchEIs	   were	   considered	   as	   a	   single	   class	   of	   drug,	   three	  separate	  AchEIs	   (donepezil,	   galantamine	  and	  rivastigmine)	  are	   the	  mainstay	   in	  AD	   therapy	   [20].	   Though	   all	   three	   drugs	   work	   similarly	   by	   inhibiting	  acetylcholinesterase	  and	  preventing	  the	  breakdown	  of	  acetylcholine	  at	  the	  post-­‐synaptic	  cleft,	  it	  is	  likely	  that	  that	  there	  are	  subtle	  differences	  in	  their	  effects	  on	  underlying	  biological	  processes.	  Therefore	  if	  an	  adequate	  sample	  size	  is	  available	  in	  future	  studies,	  all	   three	  drugs	  should	  be	  studied	  individually	  for	  their	  effects	  on	  AD	  blood	  biomarkers.	  This	  is	  pertinent	  since	  studies	  revealing	  differences	  in	  gene	   expression	   as	   a	   result	   of	   AchEI	   use	   have	   studied	   AchEIs	   individually.	  Specifically,	   Reale	   et	   al.	   [23]	   investigated	   the	   effects	   of	   donepezil	   on	   blood	  inflammatory	  markers	   in	   AD	   patients,	   while	   Andin	   et	   al.	   [38]	   investigated	   the	  effect	   of	   rivastigmine	   on	   the	   glutamate	   transporter	   rEAAC1	   blood	   mRNA	  expression	   in	   mice	   models,	   both	   revealing	   significant	   effects	   by	   the	   drugs	   on	  gene	  expression.	  	  	  One	  possible	  way	  of	  improving	  the	  sample	  size	  in	  future	  studies	  is	  to	  ensure	  the	  collection	  of	  appropriate	  medication	  information	  in	  any	  research	  cohort,	  as	  some	  subjects	   were	   excluded	   from	   our	   study	   due	   to	   incomplete	   demographic	   data.	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Furthermore	  with	  hindsight,	  medication	  could	  have	  been	  included	  as	  a	  covariate	  in	   the	   discovery	   stage	   of	   biomarker	   studies,	   instead	   of	   analyzed	   post-­‐hoc.	  We	  have	  not	  seen	  this	  approach	  applied	  in	  any	  of	  the	  discovery	  studies	  to	  date	  and	  this	  should	  therefore	  be	  considered	  for	  future	  biomarker	  studies.	  	  	  Besides	  drugs	   that	   improve	  cognitive	  symptoms,	  many	  AD	  patients	  are	  also	  on	  other	  medications	  to	  manage	  the	  non-­‐cognitive	  symptoms	  of	  the	  disease.	  People	  with	  dementia	  are	   far	  more	  susceptible	   to	  psychiatric	  conditions	  such	  as	  mood	  disorders	   and	   psychosis	   [39].	   In	   such	   cases,	   drugs	   such	   as	   antidepressants,	  neuroleptics,	  sedatives	  and	  hypnotics	  are	  often	  required	  for	  treatment	   	  [19,40].	  	  Citalopram,	   an	   antidepressant,	   has	   been	   found	   to	   affect	   gene	   expression	   in	  AD	  lymphocytes	  [41].	  Thus	  it	  is	  possible	  that	  other	  psychotropic	  medications	  could	  prove	   to	   be	   a	   confounding	   factor	   in	   blood	   biomarker	   studies	   and	   should	   be	  explored	   in	   future	   studies.	   Given	   that	   each	   subject	   could	   potentially	   be	   on	  multiple	  medications,	  it	  may	  also	  be	  possible	  to	  conduct	  multivariate	  analyses	  to	  determine	  if	  a	  combination	  of	  medications	  would	  yield	  a	  significant	  difference	  in	  gene	  expression,	  although	  larger	  cohorts	  would	  be	  needed	  to	  identify	  this.	  	  This	  study	  considered	  promising	  biomarkers	  individually,	  looking	  at	  whether	  the	  expression	   of	   single	   genes	   or	   proteins	   are	   affected	   by	   AchEIs.	   However,	  	  Sattlecker	  et	  al.	  	  [12]	  and	  Lunnon	  et	  al.	  2013	  	  [42],	  as	  well	  as	  other	  researchers,	  have	   also	   proposed	   multivariate	   biomarker	   models	   of	   AD.	   These	   multivariate	  models	   could	   also	   be	   investigated	   to	   determine	   if	   AchEIs,	   or	   any	   other	  medications,	  affect	  their	  potential	  utility.	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It	   is	   also	   important	   to	   consider	   the	   possible	   effects	   of	   medication	   on	   other	  potential	  blood	  biomarkers.	  For	  example,	  many	  other	  potential	  biomarkers	  of	  AD	  have	   been	   highlighted	   in	   recent	   reviews	   of	   blood	   gene	   expression	   	   [17]	   and	  protein	  levels	  	  [16].	  	  
5.	  Conclusion	  Overall	   this	   exploratory	   study	   has	   found	   no	   evidence	   that	   AchEIs	   are	   a	   large	  confounding	   factor	   for	   the	   most	   promising	   AD	   blood-­‐based	   biomarkers	  identified	   in	   both	   studies.	   This	   gives	   an	   encouraging	   indication	   that	   the	   use	   of	  AchEIs	  is	  unlikely	  to	  affect	  the	  validity	  of	  these	  biomarkers	  in	  potential	  diagnosis	  or	   enrichment	   applications.	   However	  more	   comprehensive	   studies	   need	   to	   be	  conducted	   to	   explore	   the	   full	   effects	   of	   AchEIs	   on	   these	   and	   other	   proposed	  blood-­‐based	  biomarkers	  of	  AD.	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Table	  1:	  Demographic	  information	  for	  subjects	  included	  in	  the	  gene	  expression	  analysis.	  
	  	   AchEI	   Non-­‐AchEI	   p-­‐value	  
Total	  Number	   72	   17	   -­‐	  
Males/Females	   25/47	   3/14	   0.25	  
Median	  Age	  (IQR)	   76	  (9.25)	   75	  (9)	   0.89	  
Median	  MMSE	  (IQR)	   22	  (7)	   22	  (6)	   0.76	  
APOE	  ε4	  Status	  
(0/1/2)	  
29/29/14	   9/7/1	   0.40	  
	  Abbreviations:	  AchEI,	  Group	  taking	  acetylecholinesterase	  inhibitors;	  Non-­‐AchEI,	  Group	  not	  on	  any	  AD	  cognitive	  enhancing	  medication;	  MMSE,	  Mini-­‐Mental	  State	  Examination.	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Table	  2:	  Results	  for	  the	  gene	  expression	  analysis	  showing	  the	  23	  probes	  analyzed	  with	  details	  of	  the	  gene	  name,	  coefficient	  value,	  standard	  error,	  p-­‐value	  and	  q-­‐value.	  
Probe	  ID	   Gene	  Name	   Coefficient	   Standard	  
Error	  
p-­‐value	   q-­‐value	  
ILMN_2097421	   MRPL51	   0.35	   0.27	   0.20	   0.29	  
ILMN_1784286	   NDUFA1	   0.40	   0.26	   0.13	   0.21	  
ILMN_1776104	   NDUFS5	   0.37	   0.27	   0.17	   0.26	  
ILMN_1726603	   ATP5I	   0.34	   0.28	   0.22	   0.30	  
ILMN_2187718	   COX17	   0.29	   0.28	   0.31	   0.36	  
ILMN_2128128	   SHFM1	   0.22	   0.27	   0.41	   0.43	  
ILMN_1799030	   CMTM2	   0.34	   0.29	   0.24	   0.30	  
ILMN_1703538	   AIF1	   0.23	   0.28	   0.41	   0.43	  
ILMN_2166865	   ENY2	   0.46	   0.27	   0.095	   0.2	  
ILMN_1732328	   LOC646200	   0.40	   0.25	   0.12	   0.21	  
ILMN_1680314	   TXN	   0.53	   0.28	   0.058	   0.15	  
ILMN_1726239	   TBCA	   0.51	   0.26	   0.054	   0.15	  
ILMN_2232936	   UQCRH	   0.53	   0.27	   0.048	   0.15	  
ILMN_1746516	   RPS25	   0.42	   0.26	   0.11	   0.21	  
ILMN_2189936	   RPL36AL	   0.071	   0.26	   0.79	   0.79	  
ILMN_1791332	   ATP5O	   0.62	   0.26	   0.022	   0.15	  
ILMN_1792528	   LOC401206	   0.50	   0.26	   0.055	   0.15	  
ILMN_2189933	   RPL36AL	   0.31	   0.26	   0.24	   0.30	  
ILMN_2225887	   ATP5EP2	   0.58	   0.27	   0.036	   0.15	  
ILMN_1661945	   C14orf156	   0.62	   0.27	   0.027	   0.15	  
ILMN_1745343	   ZMAT2	   0.54	   0.27	   0.045	   0.15	  
ILMN_1680967	   CIP29	   0.51	   0.28	   0.07	   0.16	  
ILMN_1652073	   LOC653658	   0.57	   0.25	   0.025	   0.15	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Table	  3:	  Demographic	  information	  for	  subjects	  included	  in	  the	  proteomic	  analysis.	  
	  	   AchEI	   Non-­‐AchEI	   p-­‐value	  
Total	  Number	   129	   39	   -­‐	  
Males/Females	   48/81	   9/30	   0.12	  
Median	  Age	  (IQR)	   77	  (10)	   78	  (9.5)	   0.45	  
Median	  MMSE	  (IQR)	   21	  (8)	   21	  (8)	   0.63	  
APOE	  ε4	  Status	  
(0/1/2)	  
55/48/26	   19/18/2	   0.074	  
	   Abbreviations:	  AchEI,	  Group	  taking	  acetylcholinesterase	  inhibitors;	  Non-­‐AchEI,	  Group	  not	  on	  any	  AD	  cognitive	  enhancing	  medication;	  MMSE,	  Mini-­‐Mental	  State	  Examination.	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Table	  4:	  Results	  for	  the	  proteomic	  analysis	  showing	  the	  four	  proteins	  analyzed	  with	  details	  of	  the	  UniProt	  ID,	  coefficient	  value,	  standard	  error,	  p-­‐value	  and	  q-­‐value.	  *	  Q-­‐values	  are	  approximately	  equal,	  exact	  equality	  of	  these	  Q-­‐values	  is	  an	  artifact	  of	  the	  approximation	  method	  used	  by	  the	  R	  function	  ‘p.adjust’.	  
UniProt	  ID	   Protein	  Name	   Coefficient	   Standard	  
Error	  
p-­‐value	   q-­‐value	  
P07288,	  
P01011	  
PSA-­‐ACT	   -­‐0.049	   0.19	   0.80	   0.80*	  
Q9UGM5	   Fetuin	  B	   0.083	   0.19	   0.66	   0.80*	  
P10909	   Clusterin	   0.12	   0.19	   0.54	   0.80*	  
P01298	   Pancreatic	  
Prohormone	  
0.17	   0.19	   0.37	   0.80*	  
	  	   Abbreviations:	  PSA-­‐ACT,	  prostate	  specific	  antigen	  complexed	  to	  α1-­‐antichymotrypsin	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Figure	  1:	  Statistical	  power	  curves	  for	  the	  detection	  of	  the	  effect	  of	  AchEIs	  on	  10	  blood	  markers	  (midway	  between	  number	  of	  genes	  and	  proteins	  investigated).	  Points	  indicate	  statistical	  power	  for	  different	  effect	  sizes	  (small,	  medium	  and	  large)	  in	  a	  model	  with	  6	  degrees	  of	  freedom	  for	  the	  numerator.	  Black	  lines	  indicate	  sample	  size	  of	  the	  gene	  expression	  study	  (n	  =	  89)	  and	  the	  proteomics	  study	  (n	  =	  168).	  A	  significance	  threshold	  of	  p	  <	  0.005	  was	  used	  to	  correspond	  to	  a	  p	  <	  0.05	  significance	  level	  after	  Bonferroni	  multiple	  testing	  correction	  for	  10	  markers/tests.	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Figure	  2:	  Box	  plots	  of	  the	  six	  nominally	  significant	  genes	  found	  in	  the	  gene	  expression	  analysis.	  AD	  subjects	  on	  AchEIs	  (AchEI)	  are	  compared	  with	  AD	  subjects	  not	  on	  AchEIs	  (Non-­‐AchEI)	  and	  control	  subjects	  without	  AD	  (CTL).	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There	  do	  not	  appear	  to	  be	  a	  significant	  difference	  in	  gene	  expression	  between	  AD	  subjects	  with	  and	  without	  AchEIs.	  
